Vir Biotechnology Inc

Stock Chart, Company Information, and Scan Results

$8.96(as of Mar 31, 3:58 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Vir Biotechnology Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$8.96
Ticker SymbolVIR
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees367
CountyUSA
Market Cap$1,352.0M
EBIDTA-456.3M
10-Day Moving Average8.90
P/E Ratio-2.85
20-Day Moving Average9.23
Forward P/E Ratio4.36
50-Day Moving Average8.38
Earnings per Share-3.16
200-Day Moving Average6.26
Profit Margin-66.99%
RSI51.57
Shares Outstanding159.8M
ATR0.56
52-Week High10.94
Volume1,953,218
52-Week Low4.16
Most Recent Support Level8.26
Book Value765.3M
Most Recent Resistance Level9.39
P/B Ratio1.63
Upper Keltner10.50
P/S Ratio18.20
Lower Keltner7.96
Debt-to-Equity Ratio10.50
Next Earnings Date04/30/2026
Cash Surplus141.3M
Next Ex-Dividend DateUnknown

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Vir Biotechnology Inc In Our Stock Scanner

As of Apr 01, 2026
example chart graphic
Scan Name: Heikin Ashi BreakoutScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Morning StarScan Type: Candlestick Pattern Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.